Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.85 USD | -3.46% | -2.73% | -14.33% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.33% | 464M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.00% | 21.58B | |
-10.88% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- HC Wainwright Adjusts UroGen Pharma's Price Target to $23 From $26, Keeps Buy Rating